Arcus Bioscience Stock Price, News & Analysis

Arcus Biosciences, Inc. (NYSE:RCUS) has granted stock options for a total of 31,400 shares to four new employees at an exercise price of $33.28, based on the closing price from February 23, 2021. This grant is part of the Company's 2020 Inducement Plan, approved by the Board of Directors. Arcus specializes in oncology with five clinical-stage molecules, including Etrumadenant, AB680, and Domvanalimab. The company is focused on developing innovative therapies to address significant unmet needs in cancer treatment.

Arcus Biosciences (RCUS) reported a strong financial position with $735 million in cash and a recent $220 million equity investment from Gilead. The company is advancing its pipeline, including starting registrational trials for domvanalimab and expanding clinical studies for AB680. Collaboration revenues increased to $77.5 million in 2020 from $15 million in 2019. However, R&D expenses rose significantly to $159.3 million, contributing to a net loss of $122.9 million for the year. Despite losses, positive clinical developments and strategic partnerships position Arcus for future growth.

Arcus Biosciences (NYSE:RCUS) announced upcoming presentations at key virtual investor conferences. Management will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, Cowen's 41st Annual Health Care Conference on March 2, and Barclays Global Healthcare Conference on March 10. Investors can access live audio webcasts on the Arcus website, with replays available for at least two weeks post-event. Arcus focuses on developing innovative cancer therapies, with multiple drug candidates in clinical trials addressing significant unmet needs.

Arcus Biosciences (NYSE:RCUS) announced the grant of stock options to five new employees, totaling 126,200 shares at an exercise price of $41.39, the closing price on February 8, 2021. This move is part of the Company’s 2020 Inducement Plan, aimed at attracting talent. Arcus is focused on developing cancer therapies, with four molecules in clinical trials, including Etrumadenant and AB680. The company emphasizes its commitment to addressing significant unmet needs in oncology while leveraging a robust pipeline of innovative treatments.

Arcus Biosciences (NYSE:RCUS) announced that Gilead Sciences will increase its ownership stake in the company from approximately 13% to 19.5% by purchasing 5,650,000 shares at $39.00 each. This investment highlights the partnership's strength and supports the acceleration of Arcus's clinical development plans for its four clinical-stage molecules, including AB680 for metastatic pancreatic cancer. Following this financing, Arcus expects to fund its operations through at least 2023. The ongoing collaboration is crucial for developing next-generation cancer therapies.

Arcus Biosciences (NYSE:RCUS) announced the grant of stock options to five new employees, totaling 165,300 shares at an exercise price of $38.19, based on the January 25, 2021 closing price. This grant was made under the 2020 Inducement Plan approved by the Board of Directors. The company focuses on developing innovative oncology therapies with four clinical-stage molecules, including Etrumadenant, AB680, Domvanalimab, and Zimberelimab, targeting various cancer types, illustrating its commitment to addressing significant unmet medical needs in oncology.

Arcus Biosciences (NYSE:RCUS) presented preliminary data from the ARC-8 Phase 1/1b study at ASCO 2021, focusing on the safety and efficacy of AB680, a small-molecule CD73 inhibitor, in metastatic pancreatic cancer. The study involved 19 patients receiving AB680, nab-paclitaxel, and gemcitabine. No significant additive toxicity was observed, although one patient experienced Grade 2 autoimmune hepatitis. Preliminary efficacy showed that 88% of patients had lesion shrinkage, with an overall response rate of 41%. AB680 was selected for expansion at 100mg every two weeks, showing potential for advancing treatment in this challenging cancer type.

Arcus Biosciences (NYSE:RCUS) announced the granting of stock options for 31,600 shares to three new employees, priced at $30.83 each, reflecting the company's closing share price on January 8, 2021. This initiative is part of the Company’s 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing innovative cancer therapies, with four clinical candidates under evaluation for various cancer types, including the dual A_2a/A_2b antagonist, Etrumadenant, currently in multiple Phase 2 and 1b studies.

Arcus Biosciences (NYSE:RCUS) announced promising preliminary data from its ongoing Phase 1/1b trial, ARC-8, evaluating AB680 combined with zimberelimab and chemotherapy for front-line treatment of metastatic pancreatic cancer. The data shows favorable safety and clinical activity, indicating it is well-tolerated with side effects similar to established therapies. The company plans to present detailed results at the ASCO GI symposium on January 15, 2021, and advance to the Phase 1b expansion of the study.